|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | GMP Endotherapeutics |
|---|---|
| Information provided by: | GMP Endotherapeutics |
| ClinicalTrials.gov Identifier: | NCT00034255 |
Purpose
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of intramuscular INGAP Peptide given for the first time in humans as a potential treatment for diabetes.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 |
Drug: INGAP Peptide |
Phase I Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients |
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients meeting all of the following inclusion criteria at screening can be considered for admission to the study.
Stage 1 and Stage 2:
Exclusion Criteria:
Patients meeting any of the following exclusion criteria at screening will not be enrolled in the study:
Contacts and Locations| United States, California | |
| VASDHS Medical Center | |
| San Diego, California, United States, 92161 | |
| United States, District of Columbia | |
| MedStar Research Institute - Clinical Research Center | |
| Washington, District of Columbia, United States, 20003 | |
| United States, North Carolina | |
| UNC Diabetes, Endocrinology, Metabolism Clinic | |
| Durham, North Carolina, United States, 27713 | |
| United States, Texas | |
| Texas Diabetes Institute | |
| San Antonio, Texas, United States, 78284 | |
More Information
| Study ID Numbers: | INGAP-01-001 |
| Study First Received: | April 24, 2002 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00034255 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Autoimmune Diseases Metabolic Diseases Immune System Diseases Diabetes Mellitus, Type 1 |
Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders |